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Abstract. In the present study, radioiodinated human re­
combinant interleukin-1 (IL-1) was investigated for its 
potential to image infectious foci in vivo in an animal 
model of infection. Twenty-four hours after induction of 
a Staphylococcus aureus abscess in the left calf muscle, 
mice were i.v. injected with both iodine-125 labelled IL- 
1 and iodine-131 labelled myoglobin, a size-matched 
control agent. The animals were killed for tissue biodis­
tribution studies at 2, 6 , 12, 24 and 48 h p.i. Gamma 
camera images were obtained at 6 , 24 and 48 h after in­
jecting mice with 123I-IL-1. Radioiodinated IL-1 rapidly 
cleared from the body; after 12 h the abscess was the or­
gan with the highest activity. The absolute abscess up­
take of 125I-IL-1 remained high compared to ,31I-myo- 
globin, resulting in significantly higher abscess-to-mus- 
cle ratios of 125I-IL-1 compared to l31I-myoglobin. The 
ratios of ,25I-IL-1 reached the ultimate value of 
44.4±10.8 at 48 h p.i., whereas the ratios of l31I-myoglo- 
bin did not exceed 5.9±0.7. Gamma camera imaging re­
vealed clearly visible abscesses. In conclusion, our re­
sults demonstrate specific retention of radioiodinated IL- 
1 in the abscess, presumably by interaction of IL-1 with 
its receptor on the inflammatory cells. The high target- 
to-background ratios that were obtained over the course 
of time indicate that the IL-1 receptor may be a valuable 
target for the imaging of infectious foci.
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Introduction
Adequate localization of active infectious and inflamma­
tory lesions contributes to elucidation of the cause of the 
disease and introduction of the appropriate therapy. 
However, each of the currently used radiological or scin­
tigraphic techniques for detection of infectious foci has 
limitations. In the early phase of infection, when there 
are no substantial anatomical changes, radiological tech­
niques including computerized tomography and ultraso­
nography will not reveal any abnormality. Conventional 
scintigraphic techniques, such as IgG scintigraphy and 
gallium scintigraphy can provide the information in such 
situations but these techniques require at least 24 h to es­
tablish a definitive diagnosis [ 1 ].
The ideal radiopharmaceutical for scintigraphic de­
tection of focal sites of infection should yield a same- 
day answer in order to meet the needs of clinical prac­
tice. It should therefore show high and rapid accumula­
tion in the abscess, fast blood clearance and low physio­
logical organ uptake [2]. The development of an imaging 
technique which uses a small molecule able to bind spe­
cific receptors in the infectious focus is therefore desir­
able. A possibility could be the use of cytokines. Two 
studies have recently shown that cytokines are indeed 
potential agents to image infectious foci. Firstly, Signore 
et al. showed that iodine-123 labelled IL-2 can be used 
to visualize pancreatic lymphocytic infiltration in non- 
obese diabetic mice [3]. Secondly, Hay et al. reported 
that radioiodinated IL-8 had a better performance than 
either gallium-67 citrate or indium-11 1 labelled leucocy­
tes in the detection of acute inflammatory lesions in a rat 
model [4].
In this study the potential of another radioiodinated 
cytokine, human recombinant interleukin-1, was ex­
plored. Interleukin-1 (IL-1) is a 17-kDa protein mainly 
produced by mononuclear phagocytes in response to an 
inflammatory stimulus. Two forms of IL-1 (IL-1 a  and 
IL-1 (3) have been identified. Although both forms are
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distinct gene products, they recognize the same cell sur­
face receptors and share various biological activities. Re­
cent studies have shown that two major IL-1 receptor 
(IL-1R) molecules can be distinguished. On T cells, fi­
broblasts, endothelial cells and hepatocytes, an 80-kDa 
IL-1R (type I) is consistently observed whereas neutro­
phils, monocytes and B cells express a 68 -kDa IL-IR 
(type II). The binding affinity of IL-1 for the IL-IR is in 
the picomolar range (Ka = 109— 1011 M_I), depending on 
the receptor type and IL-1 form [5|.
Infection and inflammation are characterized by an 
influx of leucocytes [6 ], being predominantly IL-IR pos­
itive cells. Because of the high affinity for its receptor, 
IL-1 might be able to specifically target to these inflam­
matory cells. The specific receptor binding may lead to a 
greater specificity for imaging inflammatory conditions. 
In addition, IL-1 rapidly clears from the blood; follow­
ing intravenous (i.v.) administration in mice, IL-1 
showed an initial half-life of 5-10 min [7]. Because of 
these favourable physicochemical characteristics, scin­
tigraphy with IL-1 may be a useful technique for early 
and specific localization of infectious foci. In the present 
study, we investigated whether radioiodinated IL-1 can 
be used to visualize infectious foci in an animal model 
of infection.
Materials and methods
Radiolabelling o f  IL-J
Human recombinant IL-1 a  (IL-1) (specific activity of 
3 x l 0 8 U/mg), kindly provided by Dr. P. Lomedico (Hoffman-La 
Roche, Nutley, N.J.), was radiolabelled using the iodogen method 
[8 ], Briefly, 3 |Ltg IL-1 (0.68 mg/ml) in 15 |il 0.5 /V/ and 70 |il 
50 m M  phosphate buffer. pH 7.2 and 37 MBq N a l25I (Amersham 
International, Amersham, UK: specific activity of 570 GBq/mg) 
were added to glass tubes, precoated with 1,3,4,6-tetrachloro- 
3cx,6a-diphenylglucouril (Pierce. Rockford, 111.) (25 j ig /100 |il). 
The reaction was allowed to proceed for 10 min at room tempera­
ture, after which the reaction mixture was eluted with 0.5% BSA 
in PBS on a Sephadex G-25 column (PD-10: Pharmacia, Uppsala, 
Sweden) to separate labelled IL-1 from free l25I. The void frac­
tions were pooled and sterilized through a 0 .2 -jim filter.
Analogously, 3 |ig myoglobin (Sigma, St. Louis, Mo.) 
(1 mg/ml), a protein with a similar molecular weight (18 kDa) to 
IL-1 without any known interactions in vivo, was labelled with 
N a ,3lI (Medgenix, Fleurus, Belgium; specific activity of 
>185 GBq/mg). Myoglobin served as the non-specific control 
agent in the biodistribution experiments.
For the purpose of gamma camera imaging, 10 jig IL-1 
(0.68 mg/ml) was labelled with 222 MBq N a l23I (Cygne, Eind­
hoven, The Netherlands, specific activity o f  > 2x 1017 Bq/mol) as 
described above.
The radiochemical purity of the radiopharmaceuticals was de­
termined by instant thin-layer chromatography (ITLC) on Gelman 
1TLC-SG strips (Gelman Laboratories, Ann Arbor, Mich.) with
0.1 M  citrate, pH 5.0, as the solvent.
Receptor binding assays
The murine cell line EL-4-6.1, a variant subline of EL-4 thymoma 
cells 19] and a kind gift from Dr. H.R. MacDonald (Ludwig Insti­
tute for Cancer Research Epalinges, Switzerland), was used for 
determination of the receptor binding capacity of the radioiodinat­
ed IL-1 preparations in vitro |10J. The cell line was cultured at 
37°C in a humidified atmosphere of a i r /C 0 2 (95:5) in RPMI 1640 
medium (GIBCO, Gaithersburg, Md.) containing 10% fetal calfCr
serum.
EL-4 binding assay. Live EL-4-6.1 cells were washed once with 
cold medium. A series of serially diluted cell suspensions 
(0 .2- 3x l 07 cells/ml) was incubated with 101000 cpm o f  radioiodi­
nated IL-1 in assay buffer (RPMI 1640, 5 mM  MgCL, 25 mM 
HEPES, 0.5% BSA, 20 jig/m 1 bacitracin (Sigma, St. Louis, Mo.). 
A duplicate o f  the lowest cell concentration was incubated in the 
presence of at least a 100-fold molar excess of unlabelled IL-1 to 
correct for non-specific binding. After 4 h incubation at 4°C. cells 
were centrifuged (5 min, 2000 g) and the radioactivity in the pel­
let (total bound radioactivity) was measured in a shielded well- 
type gamma counter (Wizard, Pharmacia-LKB, Sweden). The data 
were graphically analysed in a modified Lineweaver-Burk plot: a 
double inverse plot derived from the conventional binding plot 
(specifically bound activity versus cell concentration) [111. The 
specific binding was obtained by subtracting the non-specific 
binding from the total bound radioactivity. The receptor binding 
fraction for conditions representing infinite cell receptor excess 
was calculated by linear extrapolation to the ordinate.
Scatchard analysis. The affinity of the IL-IR  on EL-4-6.1 cells for 
radiolabelled IL-1 and the number of binding sites per cell were 
determined by means of a Scatchard analysis |12]. Briefly, live 
EL-4-6.1 cells were washed once with cold medium and incubated 
with serially diluted (1 -1000  pmol/1) l25I-IL-l. Non-specific bind­
ing was determined by incubating the EL-4-6.1 cells with labelled 
IL-1 in the presence o f  at least 100-fold excess o f  unlabelled IL-1. 
After 4 h o f  incubation at 4°C, cell-bound radioactivity was sepa­
rated from unbound 125I - IL -1 by centrifugation (5 min, 2000 g) 
and measured in the gamma counter.
B iodistribntion experimen ts
As described previously, abscesses were induced in the left calf 
muscles of ether-anaesthetized female Swiss mice (20-25  g) with 
2 x 10 colony forming units of Staphylococcus aureus in 0.05 ml 
50% -50%  suspension o f  autologous blood and normal saline 113]. 
Twenty-four hours after the inoculation of 5. aureus in the muscle, 
when swelling o f  the muscle was apparent, a 0.2 ml mixture, con­
taining 120 ng 0.4 MBq 125I-IL-1 and 120 ng 0.4 MBq 13lI-myo- 
globin, was injected in the tail vein.
Groups o f  five mice were killed under ether anaesthesia by 
cervical dislocation at 2, 6. 12, 24 and 48 h after injection of the 
radiopharmaceuticals. Blood samples, infected left calf muscle, 
right calf muscle, thymus, lungs, spleen, kidneys, liver and intes­
tines were collected. The dissected tissues were weighed and 
counted in the gam m a counter. To correct for radioactive decay, 
injection standards were counted simultaneously. The measured 
activity in tissues and samples was expressed as percentage of in­
jected dose per gram tissue (%ID/g). Abscess-to-contralateral 
muscle ratios and abscess-to-blood ratios were calculated.
Gamma camera imaging
Twenty-four hours after the induction o f  similar S. aureus infec­
tions, three Swiss mice were intravenously injected with 2 pg 
18.5 MBq 12' I - IL -1. Potassium iodide was added to the drinking 
water to a final concentration of 1% to prevent uptake of free io­
dine in the thyroid. At 6, 24 and 48 h p.i.. the mice were anaesthe-
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lizcd with fluothane (ICI Farma, Rotterdam. The Netherlands) and 
placed prone on the gam m a camera. The images were recorded 
with a standard large field of view gamma camera (Siemens Orbit- 
er, Siemens Inc., Hoffmann Estate, 111.) equipped with a parallel- 
hole medium-energy collimator. Images were obtained with a 
symmetrical 15% window over the 159-keV l23I energy peak. Af­
ter a minimum of 1501000 acquired counts, the images were digi­
tally stored in a 256x256 matrix.
The scintigraphic results were analysed by drawing regions of 
interest over the abscess, the contralateral calf muscle (back­
ground) and the whole body. Abscess-to-background ratios and 
percentage residual activity in the abscess (abscess-to-whole body 
ratio x 100%) were calculated.
Results
Statistical analysis
All values are expressed as mean ± standard error of the mean 
(SEM). Statistical analysis was performed using the repeated mea­
sures one-way analysis o f  variance (ANOVA).
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Fig. 1. A The conventional binding plot of radiolabelled IL-1. The 
specific binding over total applied radioactivity is plotted as a 
function of increasing cell concentration. The double inverse plot 
of radiolabelled IL-1 is shown in the in se t  The receptor binding 
fraction for conditions representing infinite receptor excess (r) 
was calculated by linear extrapolation to the ordinate (1 //*). B 
Scatchard analysis of radiolabelled IL-1 binding to EL-4-6.1 cells
Receptor binding assays
The labelling efficiency was always between 50% and 
80%. IL-1 was labelled with both Nal25I and Nal23I at a 
specific activity of 8-10 MBq/jig, indicating the average 
incorporation of one to two l25I or l23I atoms per IL-1 
molecule. Similarly, myoglobin was labelled with I3II at 
a specific activity of 7-8 MBq/|.ig. The radiochemical 
purity of all radiopharmaceuticals was higher than 98% 
after removal of unbound iodine.
The results of the EL-4 binding assay for radiola­
belled IL-1 are shown in Fig. 1 A. The non-specific bind­
ing was typically less than 5%. The calculated receptor 
binding fraction of radiolabelled IL-1 for conditions rep­
resenting infinite cell receptor excess was always be­
tween 70% and 95%.
Scatchard analysis of the binding data of 123I-IL-1 
(Fig. IB) revealed a dissociation constant of 
5.4x10_M mol/1. According to this analysis the EL-4-6.1 
cells displayed 4400-8500 IL-1R per cell. In addition, 
the binding of l2M-IL-l to EL-4-6.1 cells could be com­
pletely inhibited by an excess of unlabelled IL-1 (IC50 
value: 7.1 x 10“10 mol/1).
Biodistribution experiments and gamma camera imaging
Table 1 and Fig. 2 summarize the tissue biodistribution 
of radioiodinated IL-1 and myoglobin in mice with S. 
aureus infections. 125I-IL-1 rapidly cleared from the 
blood. Two hours p.i., only 2.7% ID/g remained in the 
blood, while 12 h p.i. levels had decreased to less than
0.5% ID/g. Although the majority of peripheral blood 
cells are IL-1R positive cells, separate counting of plas­
ma and cell pellet revealed that virtually all (>95%) of 
the label was found in the plasma fraction, apparently 
not cell bound. In addition, the plasma/cell pellet ratios 
for the l25I label was not significantly different from 
those for the 1311 label at all time points, indicating that 
no significant specific binding to blood cells could be 
demonstrated. The absolute uptake of l25I-IL-l rapidly 
cleared from most organs to less than 1% ID/g at 12 hCT CT
p.i. Most interestingly, from 12 h onwards the abscess is 
the organ with the highest activity.
The control agent, l3lI-myoglobin, cleared more 
slowly from the blood and hence from most organs, es­
pecially the kidneys. Most strikingly, despite the higher 
levels in the blood at all time points, no retention in the 
abscess could be observed. As shown in Fig. 3, 1311- 
myoglobin cleared from the abscess during the time 
course of the experiment. In contrast, the abscess uptake 
of l25I-IL-l decreased at early time points but stabilized 
at approximately 1% ID/g from 12 h onwards. The ab­
scess uptake of l3lI-myoglobin was significantly lower 
than that of 125I-IL-1 from 12 h onwards (P<0.05). Ab­
scess retention of l25I-IL-l and clearance of l3lI-myo-
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Table 1. Biodistribution of 125I-IL-1 and l3, I-myoglobin (%dose/g, mean values±SEM)
Organ Radiopharmaceutical 2 h p.i. 6 h p.i. 12 h p.i. 24 h p.i. 48 h p.i.
Blood '251-IL- 1 2.70 ± 0.34 1.57 ± 0 .2 4 0.38 ± 0 .2 0 0.08 ± 0.01 0.03 ± 0.004
,3, I-Myoglobin 5.09 ± 0 .3 8 2.76 ± 0 .1 2 1.22  ± 0 .1 6 0.50 ± 0.02 0.17 ± 0.004
Abscess •251-IL-1 2.54 ± 0 .2 4 1.64 ± 0 .0 9 0.96 ± 0 .1 8 0.81 ± 0 .1 5 0.76 ±0 .11
131I-Myoglobin 2.40 ± 0.24 1.52 ±  0.04 0.74 ± 0 .1 6 0.30 ± 0.03 0.15 ±0 .01
Muscle 1251-IL-1 0.66 ± 0.05 0.34 ± 0.04 0.1 1 ± 0.04 0.03 ± 0.004 0.02 ± 0.002
,31I-Myoglobin 1.20 ± 0.17 0.67 ± 0 .1 3 0 .2 1 ± 0.09 0.06 ± 0.002 0.03 ± 0.002
Thymus •251-IL- 1 1.73 ± 0 .2 4 0.81 ± 0.1 1 0.30 ± 0 .1 2 0.24 ±0 .11 0.04 ± 0.004
,3, I-Myoglobin 1.59 ± 0 .2 6 0.79 ± 0 .1 0 0.37 ± 0 .1 3 0.21 ± 0 .0 6 0.07 ±0 .01
Lung • 251-IL-1 4.31 ± 0 .4 5 1.54 ± 0 .2 3 0.41 ± 0 .1 7 0.12  ± 0.02 0.03 ± 0.004
l31I-Myoglobin 2.89 ± 0 .2 3 1.63 ±0.11 0.75 ± 0 .1 6 0.32 ± 0.02 0.11 ± 0.009
Spleen '251-IL- 1 5.36 ± 0 .6 0 1.81 ± 0 .1 8 0.50 ± 0 .1 0 0.17 ± 0.04 0.04 ± 0.004
l3, I-Myoglobin 2.45 ± 0.20 1.45 ± 0 .1 2 0.72 ±0 .11 0.36 ± 0.04 0.24 ± 0.009
Kidney '2 5 1 -IL -r 4.84 ± 0.33 1.47 ± 0 .1 3 0.51 ± 0 .1 6 0.21 ± 0.01 0.10 ± 0 .0 0 9
l31I-Myoglobin 8.72 ± 0.25 4.34 ± 0 .1 3 2.35 ±  0.22 1.53 ± 0 .0 4 0.92 ± 0.07
Liver •251-IL-1 3.12 ± 0 .2 7 0.86 ± 0.10 0.28 ± 0.08 0.10 ± 0 .0 0 9 0.05 ± 0.004
131I-Myoglobin 3.01 ± 0 .2 0 1.82 ± 0.11 1.09 ±0 .11 0.71 ± 0.02 0.46 ±0 .01
Intestine '251-IL- 1 2.59 ± 0.35 1.55 ± 0 .2 2 0.48 ± 0 .2 2 0.11  ± 0.02 0.03 ± 0.004
131I-Myoglobin 2.18 ± 0 .3 3 1.23 ± 0 .1 7 0.49 ± 0 .1 9 0.15 ± 0 .0 2 0.05 ± 0.002
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Fig. 2. Tissue uptake of l25I-IL -1 in several organs at various time 
points, expressed as %dose/g. The corresponding SEM are report­
ed in Table 1
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Fig. 3. The absolute abscess uptake of 125I- IL -1 and ,3,I-myo- 
globin at various time points, expressed as %dose/g. The error 
bars indicate SEM
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Fig. 4. Abscess-to-muscle ratios of 125I - IL -1 and I31I-myoglobin 
at various time points. The error bars indicate SEM
globin from the abscess indicate specific retention of 
,25I-IL-1 in the abscess.
As illustrated in Fig. 4, specific retention in the ab­
scess of 1251-IL-1 was also reflected in the abscess-to- 
contralateral muscle ratios. The abscess-to-contralateral 
muscle ratios of l25I-IL-l sharply rose from 3.9±0.3 at 
2 h p.i. to an ultimate value of 44.4±10.8 at 48 h p.i., 
while the ratios of l31I-myoglobin increased only slight­
ly from 2.0±0.2 to 5.9±0.7. At all time points, the ratios 
of 125I-1L-1 were significantly higher than the ratios of 
the control agent (^<0.05). Comparison of the abscess- 
to-blood ratios of both agents demonstrated that the re­
tention of l25I-IL-l in the abscess was not just caused by 
increased perfusion to the site of infection: the continu­
ously increasing abscess-to-blood ratios of 125I-IL-1 
from 1.0±0.2 at 2 h p.i. to 28.4±5.1 at 48 h p.i. were at 
all time points significantly higher than the correspond­
ing ratios of 13lI-myoglobin, which did not exceed the 
value of 0.9±0.08 (P<0.04).
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Fig. 5. Images of mice with an S. aureus 
infection in the left calf muscle, injected 
with l23I-IL -l,  at 6, 24 and 48 h p.i. The 
abscesses are indicated by the arrows. 
The retention of l23I-IL-l in the abscess 
became more prominent over a 48-h time 
span. At 48 h p.i. the mouse on the right 
showed activity at the base of the tail due 
to urinary contamination (arrowhead)
6 h 24 h 48 h
Fig. 6. Abscess-to-background ratios (solid bars) and percentage 
residual activity in the abscess (hatched bars), calculated from 
mice with an S. aureus abscess in the left calf muscle injected 
with 123I - IL -1
The accumulation in the abscess was also demonstrat­
ed by gamma camera imaging of mice injected with l23I- 
IL-1 (Fig. 5). In accordance with the biodistribution da­
ta, radiolabelled IL-1 was retained in the abscess while 
the background activity rapidly decreased. The abscess 
could therefore be clearly visualized with time. In addi- 
tioQ to accumulation of l23I-IL-l in the abscess, some 
activity uptake could be observed in the bladder and in 
the stomach (<0.1 % at 48 h p.i.).
The quantitative data derived from the images of 
three mice confirmed the observed retention of radiola­
belled IL-1 in the abscess (Fig. 6 ). A continuous in­
crease in abscess-to-background ratio from 2.4±0. 1 at 
6 h p.i. to 5.5±0.6 at 48 h p.i. could be observed. Fur­
thermore, the percentage of residual activity in the ab­
scess increased as well and reached the value of 
7.6%±0.6% at 48 h p.i.
Discussion
In this study, we investigated IL-1 as a vehicle to image 
infectious foci. Both the biodistribution and the imaging 
studies showed that radioiodinated IL-1 was retained in 
the infectious focus. The retention was specific since the
abscess uptake of IL-1 remained high as compared to the 
size-matched control agent myoglobin in spite of the 
slower clearance of myoglobin from most other tissues. 
Forty-eight hours p.i. the abscess-to-muscle ratio for IL- 
1 was more than 7 times higher than the ratio obtained 
with myoglobin (44.4±10.8 (vs) 5.9±0.7). This supports 
the hypothesis that IL-1 is retained at the infectious site 
because of interaction with its receptor on inflammatory 
cells.
The in vitro binding data demonstrated that IL-1 was 
still able to bind its receptor after the radiolabelling pro­
cedure. Several radioiodination methods, i.e. the glu- 
cose-oxidase/lactoperoxidase method, the Bolton-Hunter 
method and the iodogen method, had been compared for 
the in vitro receptor binding of radiolabelled IL-1 and 
the labelling efficiency. The iodogen method yielded the 
best results and was therefore selected. To demonstrate 
specific receptor binding of radiolabelled IL-1 in vivo in 
the abscess, we carefully searched for the proper control 
agent in the biodistribution studies. Ideally, this agent 
should have an identical molecular structure to IL-1, but 
lack the receptor binding capacity. In order to obtain 
such a control agent, we performed experiments in 
which efforts were made to heat-inactivate IL-1. The 
heat (>60°C) abolished the receptor binding capacity. 
However, size exclusion of heat-inactivated IL-1 on a 
Sephadex G75 column (Pharmacia Fine Chemicals, 
Uppsala, Sweden) showed that the heat caused protein 
aggregation. A non-denaturated size-matched protein 
without any known interactions with the IL-1R in vivo 
appeared to be the best possible alternative. Myoglobin 
met these requirements. Unfortunately, the clearance 
from the blood and most other tissues was somewhat 
slower than the clearance of radiolabelled IL-1. Most 
strikingly, however, the clearance from the abscess was 
much faster than the clearance of radiolabelled IL-1, 
supporting the concept of specific binding of IL-1 to the 
inflammatory cells in the infectious focus. Two binding 
mechanisms could theoretically play a role: (a) IL-1 
binds to IL-1 receptor positive cells in the infectious fo­
cus, and (b) IL-1 binds to these cells in the blood com­
partment followed by transport to the site of infection. 
Our results suggest that the interaction with the IL-1 re-
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ceptor takes place at the focus of infection, since no sig­
nificant binding to peripheral blood cells (<5%) could be 
demonstrated. A specific receptor binding mechanism 
may imply a greater specificity for the imaging of in­
flammation and infection than is obtained with 11'In-la­
belled human polyclonal IgG, which we currently favour 
for clinical use. We recently demonstrated that 11'In-la­
belled IgG is taken up at inflammatory sites only by vir­
tue of vascular leakage [ 13, 14].
Our pharmacokinetic data showed rapid clearance of 
125I-IL-1 from the body, which is in agreement with a 
study in uninfected mice reported by Newton et al. |7|. 
These authors found excretion of the majority of the in­
jected dose via the kidneys within the first hours follow- 
ing injection. In their study, almost all the radioactivity 
found in the urine was associated with intact 17-kDa IL-
1. Accumulation in the kidney was not observed in our 
study, indicating that radiolabelled IL-1 was rapidly ex­
creted in the urine, which is in line with the activity 
present in the bladder on our images.
The abscess-to-contralateral muscle ratio of 125I-IL-1 
of 44.4± 10.8 at 48 h p.i. in our biodistribution study was 
clearly higher than the ratios obtained with other infec­
tion detection agents, such as 11'In-labelled human poly­
clonal IeG and 99mTc-labelled leucocytes [13, 15]. Com-C  ^ L / J
parable ratios were obtained in recent studies with other 
radiopharmaceuticals: a study by Babich et al. reported a 
ratio of 33.6 after 18 h with 99mTc-labelled chemotactic 
peptides in rabbits [16], while in another study in rats a 
ratio of 35.3 was found after 24 h using 99mTc-labelled 
liposomes [17]. The background activity of 125I-IL-1 
cleared much faster than both radiolabelled chemotactic 
peptides and liposomes. In our study, the abscess was 
the organ with the highest activity after 12 h, while both 
"mTc-labelled chemotactic peptides and liposomes show 
high uptake in the mononuclear phagocytic system ] 18], 
as can also be seen on the images obtained with these 
agents. The fast whole body clearance and the retention 
in the abscess of l23I-IL-l resulted in clearly delineated 
abscesses. The modest uptake in the stomach on our im­
ages is due to a certain decree of dehalosenation, as is 
generally recognized for radioiodinated proteins.
The rapid clearance resulted in a low absolute uptake 
of radiolabelled IL-1 in the abscess. Therefore, to apply 
radiolabelled IL-1 clinically for scintigraphic visualiza­
tion of infectious foci, high doses of radioactivity and 
subsequently high doses of IL-1 would have to be ad­
ministered. The latter will interfere with clinical applica­
tion because of the side-effects of systemically adminis­
tered IL-1. Fever, headache, increased sensitivity to pain 
and hypotension are commonly seen when IL-1 is ad­
ministered to patients even at doses as low as 
10-100 ng/kg 119]. Obviously, these are unacceptable 
side-effects for an imaging agent. They might be circum­
vented by using a molecule that binds to the IL-1R with 
the same affinity, without inducing biological reponses. 
Site-directed mutagenesis has elucidated particular ami­
no acid residues in the IL-1 molecule which affect the
bioactivity. Conversion of arginine-127 to glycine-127 in 
the mature human interleukin- 1 b protein reduced bioac­
tivity by 100-fold while the receptor binding activity de­
creased by only 25% [20]. Similarly, Camacho et al. 12 1 ] 
produced the Thr9Gly mutant of IL-1 (3 of which the bio­
logical activity had been reduced 200-fold without di­
minishing the receptor binding. Furthermore, a few years 
ago an IL-1 receptor antagonist (IL-lra) was identified. 
This 22- to 25-kDa molecule, structurally related to IL- 
l a  and IL-1 (3, binds to IL-1 type 1 receptors with equal 
affinity without inducing any discernible biological re­
sponses 122]. In fact, healthy human volunteers have re­
ceived doses of IL-lra of up to 10 mg/kg without any 
clinical or laboratory changes [23]. The use of radiola­
belled IL-lra in our animal model is currently under in­
vestigation.c
In summary, this study shows specific retention of IL-
1 in S. aureus-induced infectious foci in a mouse model. 
The hi eh target-to-background ratios that were obtained 
over the course of time indicate that the IL-1 receptor 
may be a valuable target for the imaging of infectious 
foci. In order to further explore the hypothesis that the 
retention of IL-1 "is caused by specific receptor binding, 
we plan to study the effect of blockade of IL-1 receptors 
with anti-IL-1 receptor antibodies. In addition, the rela­
tionship between inflammatory cells and radiolabelled 
IL-1 will also be studied by means of autoradiography. 
Furthermore, future studies are required to develop a ra­
diopharmaceutical directed towards the same target but 
lackine the clinical side-effects of IL-1.
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